{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:48:50Z","timestamp":1777938530775,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"DOI":"10.7759\/cureus.108121","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:42:11Z","timestamp":1777696931000},"source":"Crossref","is-referenced-by-count":0,"title":["Images in Medicine: Recognizing Hereditary Hemorrhagic Telangiectasia Through Mucocutaneous Findings and Its Management Challenges"],"prefix":"10.7759","author":[{"given":"Stephanie","family":"Khodzandi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Rajib","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Moritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahzabin","family":"Kibria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mccomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00585-z","article-title":"Hereditary haemorrhagic telangiectasia","volume":"11","author":"Hermann R","year":"2025","unstructured":"Hermann R, Shovlin CL, Kasthuri RS, et al.. Hereditary haemorrhagic telangiectasia. Nat Rev Dis Primers. 2025, 11:1. 10.1038\/s41572-024-00585-z","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1443","article-title":"Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia","volume":"173","author":"Faughnan ME","year":"2020","unstructured":"Faughnan ME, Mager JJ, Hetts SW, et al.. Second international guidelines for the diagnosis and management of hereditary hemorrhagic telangiectasia. Ann Intern Med. 2020, 173:989-1001. 10.7326\/M20-1443","journal-title":"Ann Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.02.021","article-title":"Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the US Multi-Society Task Force on Colorectal Cancer","volume":"162","author":"Boland CR","year":"2022","unstructured":"Boland CR, Idos GE, Durno C, et al.. Diagnosis and management of cancer risk in the gastrointestinal hamartomatous polyposis syndromes: recommendations from the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2022, 162:2063-85. 10.1053\/j.gastro.2022.02.021","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15732-2","article-title":"A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4)","volume":"363","author":"Gallione CJ","year":"2004","unstructured":"Gallione CJ, Repetto GM, Legius E, et al.. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004, 363:852-9. 10.1016\/S0140-6736(04)15732-2","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109632","article-title":"Phenotypic characterisation of SMAD4 variant carriers","volume":"61","author":"Caillot C","year":"2024","unstructured":"Caillot C, Saurin JC, Hervieu V, et al.. Phenotypic characterisation of SMAD4 variant carriers. J Med Genet. 2024, 61:734-40. 10.1136\/jmg-2023-109632","journal-title":"J Med Genet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62584","article-title":"Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations","volume":"188","author":"Balachandar S","year":"2022","unstructured":"Balachandar S, Graves TJ, Shimonty A, et al.. Identification and validation of a novel pathogenic variant in GDF2 (BMP9) responsible for hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations. Am J Med Genet A. 2022, 188:959-64. 10.1002\/ajmg.a.62584","journal-title":"Am J Med Genet A"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62522","article-title":"Clinical manifestations of patients with GDF2 mutations associated with hereditary hemorrhagic telangiectasia type 5","volume":"188","author":"Farhan A","year":"2022","unstructured":"Farhan A, Yuan F, Partan E, Weiss CR. Clinical manifestations of patients with GDF2 mutations associated with hereditary hemorrhagic telangiectasia type 5. Am J Med Genet A. 2022, 188:199-209. 10.1002\/ajmg.a.62522","journal-title":"Am J Med Genet A"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000281","article-title":"Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management","volume":"2021","author":"Hammill AM","year":"2021","unstructured":"Hammill AM, Wusik K, Kasthuri RS. Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management. Hematology Am Soc Hematol Educ Program. 2021, 2021:469-77. 10.1182\/hematology.2021000281","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2026033112","article-title":"Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS)","author":"Al-Samkari H","year":"2026","unstructured":"Al-Samkari H, Friday C, Kasthuri RS, et al.. Clinical spectrum of hereditary hemorrhagic telangiectasia: data from the Comprehensive HHT Outcomes Registry of the US (CHORUS). Blood. 2026, 10.1182\/blood.2026033112","journal-title":"Blood"},{"key":"ref10","article-title":"Hereditary hemorrhagic telangiectasia","author":"McDonald J","year":"2026","unstructured":"McDonald J, Gossage JR, Stevenson DA. Hereditary hemorrhagic telangiectasia. GeneReviews. Adam MP, Bick S, Mirzaa GM, et al. (ed): University of Washington, Seattle, WA; 2026."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312749","article-title":"Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia","volume":"391","author":"Al-Samkari H","year":"2024","unstructured":"Al-Samkari H, Kasthuri RS, Iyer VN, et al.. Pomalidomide for epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med. 2024, 391:1015-27. 10.1056\/NEJMoa2312749","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2025000698","article-title":"What's new in hereditary hemorrhagic telangiectasia?","volume":"2025","author":"Kasthuri RS","year":"2025","unstructured":"Kasthuri RS. What's new in hereditary hemorrhagic telangiectasia?. Hematology Am Soc Hematol Educ Program. 2025, 2025:131-6. 10.1182\/hematology.2025000698","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0061","article-title":"Genetic\/familial high-risk assessment: colorectal, endometrial, and gastric, version 3.2024, NCCN Clinical Practice Guidelines In Oncology","volume":"22","author":"Hodan R","year":"2024","unstructured":"Hodan R, Gupta S, Weiss JM, et al.. Genetic\/familial high-risk assessment: colorectal, endometrial, and gastric, version 3.2024, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2024, 22:695-711. 10.6004\/jnccn.2024.0061","journal-title":"J Natl Compr Canc Netw"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23147","article-title":"Laser-assisted control of epistaxis in hereditary hemorrhagic telangiectasia: a systematic review","volume":"52","author":"Abiri A","year":"2020","unstructured":"Abiri A, Goshtasbi K, Maducdoc M, Sahyouni R, Wang MB, Kuan EC. Laser-assisted control of epistaxis in hereditary hemorrhagic telangiectasia: a systematic review. Lasers Surg Med. 2020, 52:293-300. 10.1002\/lsm.23147","journal-title":"Lasers Surg Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29701","article-title":"Sclerotherapy versus cautery\/laser treatment for epistaxis in hereditary hemorrhagic telangiectasia","volume":"132","author":"Woodard TD","year":"2022","unstructured":"Woodard TD, Yappel-Sinkko KB, Wang X, McCrae KR, Parambil JG. Sclerotherapy versus cautery\/laser treatment for epistaxis in hereditary hemorrhagic telangiectasia. Laryngoscope. 2022, 132:920-5. 10.1002\/lary.29701","journal-title":"Laryngoscope"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/00034894221078075","article-title":"Sclerotherapy for hereditary hemorrhagic telangiectasia-related epistaxis: a systematic review","volume":"132","author":"Thiele B","year":"2023","unstructured":"Thiele B, Abdel-Aty Y, Marks L, Lal D, Marino M. Sclerotherapy for hereditary hemorrhagic telangiectasia-related epistaxis: a systematic review. Ann Otol Rhinol Laryngol. 2023, 132:82-90. 10.1177\/00034894221078075","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1258\/ar.2011.110132","article-title":"Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization","volume":"52","author":"Trojanowski P","year":"2011","unstructured":"Trojanowski P, Jargiello T, Trojanowska A, Klatka J. Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization. Acta Radiol. 2011, 52:846-9. 10.1258\/ar.2011.110132","journal-title":"Acta Radiol"},{"key":"ref18","article-title":"Percutaneous embolization on hereditary hemorrhagic telangiectasia patients with severe epistaxis","volume":"47","author":"Braak SJ","year":"2009","unstructured":"Braak SJ, de Witt CA, Disch FJ, Overtoom TT, Westermann JJ. Percutaneous embolization on hereditary hemorrhagic telangiectasia patients with severe epistaxis. Rhinology. 2009, 47:166-71.","journal-title":"Rhinology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12654","article-title":"Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease","volume":"12","author":"Gaillard S","year":"2014","unstructured":"Gaillard S, Dupuis-Girod S, Boutitie F, et al.. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost. 2014, 12:1494-502. 10.1111\/jth.12654","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.06.012","article-title":"Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study","volume":"134","author":"Geisthoff UW","year":"2014","unstructured":"Geisthoff UW, Seyfert UT, K\u00fcbler M, Bieg B, Plinkert PK, K\u00f6nig J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res. 2014, 134:565-71. 10.1016\/j.thromres.2014.06.012","journal-title":"Thromb Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.261859","article-title":"An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study","volume":"106","author":"Al-Samkari H","year":"2021","unstructured":"Al-Samkari H, Kasthuri RS, Parambil JG, et al.. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica. 2021, 106:2161-9. 10.3324\/haematol.2020.261859","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13714","article-title":"Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial","volume":"294","author":"Dupuis-Girod S","year":"2023","unstructured":"Dupuis-Girod S, Rivi\u00e8re S, Lavigne C, et al.. Efficacy and safety of intravenous bevacizumab on severe bleeding associated with hemorrhagic hereditary telangiectasia: a national, randomized multicenter trial. J Intern Med. 2023, 294:761-74. 10.1111\/joim.13714","journal-title":"J Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/466433-images-in-medicine-recognizing-hereditary-hemorrhagic-telangiectasia-through-mucocutaneous-findings-and-its-management-challenges","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:42:20Z","timestamp":1777696940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/466433-images-in-medicine-recognizing-hereditary-hemorrhagic-telangiectasia-through-mucocutaneous-findings-and-its-management-challenges"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.108121","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}